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j Abstract Objective The primary
objective of this study was to assess
the impact of atomoxetine in combi-
nation with psychoeducation, com-
pared with placebo and
psychoeducation, on health-related
quality of life (HRQL) in Swedish
stimulant-naı¨ve pediatric patients
with attention deficit/hyperactivity
disorder (ADHD). HRQL results will
be presented elsewhere. Here, psy-
choeducation as well as efficacy and
safety of the treatment are described.
Patients and methods A total of
99 pediatric ADHD patients were
randomized to a 10-week double-
blind treatment with atomoxetine
(49 patients) or placebo (50 pa-
tients). Parents of all patients
received four sessions of psycho-
education. Atomoxetine was dosed
up to approximately 1.2 mg/kg
day (£70 kg) or 80 mg/day
(>70 kg). Improvement of ADHD
symptoms was evaluated using the
ADHD rating scale (ADHD-RS)
and clinical global impression
(CGI) rating scales. Safety was
assessed based on adverse events
(AEs). Results The study popula-
tion was predominantly male
(80.8%) and diagnosed with the
combined ADHD subtype (77.8%).
The least square mean (lsmean)
change from baseline to endpoint
in total ADHD-RS score was )19.0
for atomoxetine patients and )6.3
for placebo patients, resulting in
an effect size (ES) of 1.3 at end-
point. Treatment response
(reduction in ADHD-RS score of
‡25 or ‡40%) was achieved in 71.4
or 63.3% of atomoxetine patients
and 28.6 or 14.3% of placebo
patients. The lsmean change from
baseline to endpoint in CGI-
Severity was )1.8 in the atomoxe-
tine group compared with )0.3 in
the placebo group. The difference
between treatments in CGI-
Improvement at endpoint was
)1.4 in favor of atomoxetine. No
serious AEs occurred. The safety
profile of atomoxetine was in line
with the current label. Conclu-
sions Atomoxetine combined
with psychoeducation was supe-
rior to placebo and psychoeduca-
tion in ADHD core symptoms
improvement. The large ES might
be a result of including stimulant-
naı¨ve patients only, but also may
indicate a positive interaction
between atomoxetine treatment
and psychoeducation, possibly by
increased compliance.
j Key words ADHD –
atomoxetine – clinical research/
trial – parenting education –
pharmacotherapy
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Introduction
Attention deficit/hyperactivity disorder (ADHD) is
the most commonly diagnosed neurodevelopmental
disorder in children and adolescents, with 3–8% of all
school-aged children being affected [1, 2]. ADHD is
often associated with prominent psychiatric co-mor-
bidities, such as oppositional defiant disorder (ODD),
conduct disorder, tics and sleep disorders, learning
disorder, and motor problems [3–5]. Children and
adolescents with ADHD are at high risk for a wide
range of adverse psychiatric outcomes including
markedly elevated rates of antisocial, addictive, mood
and anxiety disorders [6], and frequently suffer
from impairment in school performance, family
and peer relations, and higher proneness for injury,
which leads to poor health related quality of life
(HRQL) [7, 8].
Current treatments include pharmacotherapy,
behavioral, and psychosocial interventions [9]. In
2002, atomoxetine was approved in the US as the first
non-stimulant compound for treatment of ADHD.
Compared with stimulants, atomoxetine has a rela-
tively slow onset of action (days–weeks compared
with minutes–hours) [7, 10]. Administered once-daily
in the morning, it provides continuous symptom re-
lief that lasts not only into the evening hours but also
into the morning hours [11]. Atomoxetine was proven
to be a well-tolerated and efficacious treatment for
ADHD in the first six acute placebo-controlled stud-
ies, in which it was always statistically superior to
placebo [11–15]. Currently it presents by far the most
extensively studied pharmacotherapeutic drug in
clinical trials on children with ADHD [16]. Meanwhile
atomoxetine is approved in most European countries
for treatment of pediatric and adolescent ADHD pa-
tients.
The primary objective of the present study was to
explore the changes in HRQL, or the ‘‘broader effi-
cacy’’, of atomoxetine compared with placebo in
Swedish children and adolescents, primarily mea-
sured by the Children’s Health and Illness Profile,
Child Edition, Parent Reported (CHIP-CE) [17,
18]. These results will be reported separately. This
manuscript will present and discuss the effect of
atomoxetine combined with psychoeducation com-
pared with placebo combined with psychoeducation
on core ADHD symptoms and on safety measures in
a stimulant-naı¨ve population; in spite of the large
number of placebo-controlled clinical trials with
atomoxetine, no previous trial has included only
stimulant-naı¨ve patients. Inclusion of previously
stimulant-treated patients may introduce heteroge-
neity in a study population that is difficult to control,
since these patients (and/or their caregivers) are likely
to be dissatisfied with at least some efficacy aspect or
with the side effect profile of the previous treatment;
thus they may represent a more treatment-resistant
population. In addition, previously stimulant-treated
patients and their caregivers are used to an almost
instantaneous treatment effect and may therefore
have very different expectations on the treatment ef-
fect of atomoxetine when compared with a treatment-
naı¨ve population [19]. Consequently, study results
obtained exclusively from stimulant-naı¨ve patients
are more likely to give an unbiased picture of the
efficacy and safety of atomoxetine when given as a
‘‘first-line’’ treatment.
European regulatory authorities require a com-
prehensive treatment program for ADHD, which, in
addition to the pharmacological treatment, includes
psychological, educational and social measures
[10]. To account for that, we developed a psychoed-
ucational program which was mandatory for all pa-
tients’ caregivers during the double-blind treatment
phase.
Methods
j Study design
This multi-center, randomized, double-blind, pla-
cebo-controlled, Phase 3b study (B4Z-SO-LY15) was
conducted in Swedish pediatric ADHD patients. It was
designed as a 3-period study, consisting of a screening
period (study period I), a placebo-controlled, double-
blind treatment period (study period II), and an op-
tional open-label long-term extension period (study
period III). Results discussed here include study
periods I and II only.
j Abbreviations ADHD: Attention
deficit/hyperactivity disorder, ADHD-
RS: Attention deficit/hyperactivity
disorder rating scale, AE: Adverse
event, ANCOVA: Analysis of covari-
ance, ANOVA: Analysis of variance,
CD: Conduct disorder, CGI-I: Clini-
cal global impression-improvement,
CGI-S: Clinical global impression-
severity, DSM-IV: Diagnostic and
statistical manual of mental disor-
ders, 4th edition, ES: Effect size,
K-SADS-PL: Kiddie schedule for
affective disorders and schizophre-
nia for school-age children-present
and lifetime version, LOCF: Last
observation carried forward,
MMRM: Mixed-model repeated
measures, ODD: Oppositional defi-
ant disorder, HRQL: Health-related
quality of life
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j Study population and recruitment
The study was conducted at nine outpatient investi-
gative sites in Sweden. At Screening (visit 1), patients
were assessed for eligibility. Male and female patients
7–15 years of age were included if they met the cri-
teria for ADHD of the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-
IV) and had a severity threshold of 1.5 standard
deviations above the US age and gender norms for
their diagnostic subtype on the ADHD rating scale-
parent version: Investigator Administered and Scored.
The diagnoses of ADHD and comorbidities were
based on a clinical interview and confirmed by the
Kiddie Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children-Present and Lifetime
Version (K-SADS-PL [20]). The screening forms for
affective (but not anxiety) and neuropsychiatric dis-
orders were used for all patients, and a positive
screening diagnosis was further confirmed by a more
thorough interview, using the corresponding supple-
ment. Eligible patients had to be stimulant-naı¨ve.
Important exclusion criteria included general
impairment of intelligence, as clinically assessed by
the investigator, serious medical illness, a history of
psychosis or bipolar disorder, alcohol or drug abuse
within the previous 3 months, or ongoing use of
psychoactive medication other than the study drug.
Patients who required immediate pharmacotherapy
or structured psychotherapy were also excluded.
Prior to any study-related procedures, written in-
formed consent was obtained from each patient’s
caregiver and written assent was obtained from the
patients. The study was conducted in compliance with
good clinical practice guidelines and in accordance
with the ethical standards of the 1975 Declaration of
Helsinki, as revised in 2002. The study protocol was
reviewed and approved by the Ethical Review Board
in Go¨teborg.
j Study treatments
During the double-blind study period II, patients re-
ceived either atomoxetine or placebo for 10 weeks.
Randomization using an interactive voice system,
stratified by site, was performed at visit 2 (week 0).
Starting the day after visit 2, all patients took
two capsules of study mediation in the morning.
During week 1, atomoxetine patients weighing not
more than 70 kg received a dose of 0.5 mg/kg day and
patients weighing >70 kg a dose of 40 mg/day. After
the first week, the dose was increased to 1.2 mg/kg
day (weight of £70 kg) or 80 mg/day (>70 kg). Ato-
moxetine capsules of 2.5, 5, 10, 20, 25, and 40 mg as
well as identical placebo capsules were available in
blister packs. Patients were assessed during study
period II at weeks 1, 3, 5, 7, and 10 (visits 3–7).
In addition to pharmacotherapy, treatment in-
cluded a psychoeducational program for the patients’
caregivers of both treatment groups. This program,
developed by a professional educational manager,
consisted of four 3-h sessions and was specifically
adapted to the conditions associated with this clinical
study in children and adolescents. It aimed to
improve the caregivers’ knowledge and understanding
of ADHD and the implications of the disorder on the
child’s everyday functioning, to increase the caregiv-
ers’ awareness of how they can adjust the environ-
ment to the child’s functional level, to provide
guidance on how to facilitate and promote positive
parent-child interaction and positive behavioral pat-
terns, to give an introduction on how behavior
modification principles can be applied in handling the
child’s problem behavior, and to guide and inform
about available social and educational support and
health care. Methods included introductory lectures,
group discussions, problem solving, modeling, and
role plays based on real life situations. Each session
was conducted by one or two group leaders with
various professional backgrounds (psychologists, so-
cial workers, special educators, and psychiatric nur-
ses), who had broad experience with ADHD patients
and were familiar with psychosocial treatment based
on behavioral principles. All group leaders had to
participate in a specific 2-day training supervised by
the educational manager before the start of the trial.
All information provided in slides and printed
material was standardized, and all sites used the same
educational material. After the last session, the care-
givers received an evaluation form for assessment of
the psychoeducational program. Although this eval-
uation was not planned in the study protocol and
consequently not monitored by the study sponsor, the
key findings will be presented here.
After completion of study period II, patients of
both treatment groups were offered to enter the open-
label study period III extension, during which all
patients received atomoxetine until it became com-
mercially available in Sweden, but for no longer than
9 months.
j Assessments
Efficacy on core ADHD symptoms was assessed using
the ADHD rating scale-IV parent version (ADHD-RS),
which evaluates all 18 symptoms of the DSM-IV
ADHD diagnosis [21, 22]. An improvement is indi-
cated by a decrease in scores. The original form was
translated to Swedish, and then translated back to
English. The Swedish translation then received ap-
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proval by the copyright holder (Guilford Press, New
York, NY, USA). The ADHD-RS was applied and
scored by qualified site personnel at each study visit.
The inter-rater agreement was very high at a rater
training session conducted prior to the start of the
study (intraclass correlations coefficients of 0.82–1.0).
Further efficacy assessments included the clinical
global impression-severity (CGI-S) scale [23], a sin-
gle-item expert rating of the severity of the patient’s
ADHD symptoms, and the clinical global impression-
improvement (CGI-I) scale [23], a single-item expert
rating of the total improvement (or worsening) of the
patient’s symptoms since the beginning of treatment.
CGI-S is rated on a seven-point scale, where
1 = normal, not all at all, and 7 = among the most
extremely ill patients. CGI-I is rated on a seven-point
scale, where 1 = very much improved, 4 = no change,
and 7 = very much worsened. Safety was evaluated by
monitoring adverse events (AEs) throughout the
study. Compliance was assessed by direct questioning
and upon review of returned medications and was
defined as taking 70–130% of the study drug dosage
prescribed for that particular visit interval.
j Analyses
Sample size considerations were based on the primary
objective of this study (HRQL as measured by the
CHIP-CE Achievement domain) and will be reported
with the respective results elsewhere. Demographics
and baseline characteristics were summarized
descriptively. Baseline was defined as the last assess-
ment prior to or on the day of randomization (vis-
it 2). For the efficacy variables ADHD-RS and CGI-S,
the last observation carried forward (LOCF) change
from baseline to endpoint (visit 7 at week 10) was
analyzed using an analysis of covariance (ANCOVA)
model including terms for baseline, treatment, and
site. The endpoint value for CGI-I was analyzed using
an analysis of variance (ANOVA) model including
terms for treatment and site. In addition, a restricted
maximum likelihood based mixed-model repeated
measures (MMRM) model with terms for treatment,
site, visit, and baseline (assuming no specific covari-
ance structure) was applied for post-baseline scores
using PROC MIXED in the SAS software system.
Further statistical tests included the t-test for con-
tinuous and Fisher’s exact test for binary outcomes.
All statistical significance tests were 2-sided with a
nominal significance level of 5%. The effect size (ES)
was calculated by dividing the model based difference
between the groups at each visit by the standard
deviation of the corresponding residuals, and by
using the LOCF change from baseline to endpoint
ANCOVA.
All randomized patients who had at least a baseline
and one post-baseline measurement in study period
II were included in the efficacy analyses. Analysis of
safety included all patients who took at least one dose
of study medication.
Results
j Patients
Of the 102 screened patients, 99 met the entry criteria
and were randomized to atomoxetine (49 patients) or
placebo (50 patients). All 99 patients completed the
double-blind study period II and entered the open-
label study period III. The study cohort is summa-
rized in Fig. 1. Both treatment groups were compa-
rable in terms of demographics and baseline
characteristics (Table 1).
j Medication and treatment compliance
The mean doses prescribed at baseline were 0.7 mg/
kg (SD = 0.1), this increased to 1.2 mg/kg (SD = 0.2,
0.1) at weeks 1 and 3 (visits 3, 4) and 1.1 mg/kg
(SD = 0.2) for the final 5 weeks of double-blind
treatment. The dose range during the last 7 weeks of
the trial was 0.6–1.4 mg/kg. Three atomoxetine-trea-
ted patients at week 5 and one atomoxetine-treated
patient at week 7 needed dose adjustments (reduction
Study Period I
Patients screened
N=102
Screening failures
N=3
(entry criteria not met)
Study Period II
Patients randomized
N=99
Atomoxetine
N=49
Completed
Study Period II
N=49
Completed
Study Period II
N=50
Study Period III
(all atomoxetine)
N=99
Placebo
N=50
Fig. 1 Patient disposition flowchart
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of the dose within the dose range of 0.5–1.2 mg/kg
day was allowed for side effect control). Three pa-
tients were not compliant (i.e. <70 or >130% of the
prescribed study drug was taken) with the dosing
regimen (one atomoxetine patient at week 10, one
placebo patient at weeks 3 though 10, and another
placebo patient at week 10).
j Efficacy results
Mean ADHD-RS scores at baseline were similar for
both treatment groups. At endpoint, the ADHD-RS
total score had improved with atomoxetine (lsmean
change from baseline: )19.0) and to a lesser extent
with placebo (lsmean change: )6.3) (Table 2). This
difference between treatments as well as the between-
treatment differences in the change from baseline to
endpoint for the inattention and hyperactivity-
impulsivity subscale scores were statistically signifi-
cant in favor of atomoxetine (all P < 0.001).
Analysis of the CGI scores confirmed the statisti-
cally significant superior efficacy of atomoxetine over
placebo seen in the ADHD-RS total and sub-scores. An
improvement from baseline to endpoint in the CGI-S
score was observed in the atomoxetine group with an
lsmean change of )1.8, whereas in the placebo group
the score changed only slightly ()0.3). This between-
treatment difference of )1.5 points at endpoint was
statistically significant (P < 0.001) (Table 2). Simi-
larly, the difference between atomoxetine and placebo
in CGI-I was also statistically significant at endpoint in
favor of atomoxetine (lsmean of 2.3 vs. 3.7; P < 0.001;
Table 2).
Results from the MMRM analyses showed that the
mean ADHD-RS total scores decreased (improved) at
each visit during study period II with both treatments
(Fig. 2). However, in the atomoxetine group, de-
creases were larger between visits compared with
placebo, and the most pronounced decrease occurred
during the first 3 weeks. As a result, the difference
between treatments in the ADHD-RS total score was
statistically significant at each visit (P < 0.001) from
visit 4 (week 3) onwards. This was also reflected in
the corresponding ES of atomoxetine compared with
placebo in the ADHD-RS total score, which increased
at each visit and reached a value of 1.3 at week 10, the
end of study period II (Fig. 2).
The proportion of patients responding to treat-
ment, defined a priori as a ‡25 or ‡40% improvement
from baseline to endpoint of the ADHD-RS total
score, were considerably higher among atomoxetine
patients [35 patients (71.4%) and 31 (63.3%)] than
Table 2 Scores for the assessment of the ADHD core symptoms at baseline and changes from baseline to endpoint
Baseline score Change from baselinea
Mean (SD) LS mean (SE) Difference in LS means
Atomoxetine (N = 49) Placebo (N = 50) Atomoxetine (N = 49) Placebo (N = 50) Estimate (95% CI) P-value
ADHD-RS Score
Total 38.9 (7.7) 39.5 (6.7) –19.0 (1.5) )6.3 (1.5) )12.8 ()16.8; )8.8) <0.001
Inattention subscale 21.3 (4.1) 21.5 (3.7) )10.3 (0.8) )3.8 (0.7) )6.5 ()8.6; )4.5) <0.001
Hyperactivity-impulsivity subscale 17.6 (6.4) 18.0 (5.9) )8.7 (0.8) )2.5 (0.8) )6.2 ()8.5; )4.0) <0.001
CGI-Severity 4.8 (0.7) 4.9 (0.7) )1.8 (0.1) )0.3 (0.1) )1.5 ()1.9; )1.1) <0.001
CGI-Improvementa – 2.3 (0.2) 3.7 (0.2) )1.4 ()1.8; )1.0) <0.001
N total number of patients, SD standard deviation, LS least square, SE standard error, CI confidence interval, CGI clinical global impression
aFor CGI-improvement values at endpoint are given which reflect the change from baseline as defined by the instrument (1 = very much improved; …; 4 = no
change; …; 7 = very much worsened)
Table 1 Demographics and baseline characteristics
Parameter Atomoxetine
(N = 49)
Placebo
(N = 50)
Total
(N = 99)
Gender n (%)
Female 10 (20.4) 9 (18.0) 19 (19.2)
Male 39 (79.6) 41 (82.0) 80 (80.8)
Ethnic origin n (%)
African 0 1 (2.0) 1 (1.0)
Caucasian 44 (89.8) 49 (98.0) 93 (93.9)
Asian 3 (6.1) 0 3 (3.0)
Other 2 (4.1) 0 2 (2.0)
Age group n (%)
6–11 years 24 (49.0) 32 (64.0) 56 (56.6)
12–15 years 25 (51.0) 18 (36.0) 43 (43.4)
Mean Age (SD) years 11.6 (2.3) 11.3 (2.1) 11.5 (2.2)
DSM-IV ADHD subtype n (%)
Combined 37 (75.5) 40 (80.0) 77 (77.8)
Hyperactive 2 (4.1) 2 (4.0) 4 (4.0)
Inattentive 10 (20.8) 8 (16.0) 18 (18.2)
Comorbid conditions n (%)
Depression 2 (4.1) 3 (6.0) 5 (5.1)
Oppositional/defiant disorder 11 (22.4) 9 (18.0) 20 (20.2)
Tics (any type) 6 (12.2) 8 (16.0) 14 (14.1)
Motoric tics 6 (12.2) 8 (16.0) 14 (14.1)
Phonetic tics 4 (8.2) 7 (14.0) 11 (11.1)
There were no statistically significant between-group differences for any
characteristics at baseline
N total number of patients, n number of patients with available data, SD
standard deviation
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among placebo patients [14 (28.6%), 7 (14.3%);
P < 0.001 for both treatment comparisons].
Results from the repeated measures analysis of the
CGI-I were similar to those seen in the ADHD-RS,
with statistically significant between-treatment dif-
ferences in favor of atomoxetine at each visit
(P < 0.001) from visit 4 (week 3) onwards (Fig. 3). In
contrast to a continued improvement in the ato-
moxetine group, the CGI-I score in the placebo group
did not show any further improvement after its first
assessment at visit 3 (week 1).
j Evaluation of parental psychoeducation
The global parental assessment of most aspects of
psychoeducation was very positive. Items were mostly
rated as ‘‘very good/very satisfied’’ or ‘‘rather good/
satisfied’’ (in the absolute majority of assessments,
including questions about increased knowledge on
the disorder, ways of coping with it, and how to
prevent problematic behavior). Regarding questions
about the change of the children’s functioning, the
majority of parents still noted an improvement,
although the proportion of more negative answers
was higher. The evaluation was not monitored by the
study sponsor, and therefore no absolute numbers are
presented here.
j Safety results
Treatment with atomoxetine was well tolerated. No
patients discontinued during the double-blind treat-
ment phase. Forty-four patients (89.8%) on ato-
moxetine and 37 patients (74.0%) on placebo reported
one or more AEs (P = 0.066). The most common AEs
reported for atomoxetine-treated patients were head-
ache, abdominal pain upper, fatigue, anorexia, and
nausea (Table 3). With the exception of fatigue, pro-
portions of patients with these AEs were statistically
significantly higher in the atomoxetine group than in
the placebo group. There were no statistically signifi-
cant differences between treatment groups regarding
the incidence for other AEs. The AEs reported with a
frequency of ‡5% in the atomoxetine group were in
line with the atomoxetine SPC [10]. No serious AEs
were reported during study period II.
Mean changes from baseline to endpoint of study
period II in systolic blood pressure were 1.4 mmHg
for atomoxetine and 0.3 mmHg for placebo. Corre-
sponding mean changes in diastolic blood pressure
were 2.0 mmHg for atomoxetine and )1.8 mmHg for
placebo. Mean changes from baseline to endpoint in
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Table 3 Adverse events reported for ‡5% of patients in any treatment group
Preferred term Number (%) of patients P-value
Atomoxetine
(N = 49)
Placebo
(N = 50)
Total
(N = 99)
Patients with ‡1 TEAE 44 (89.8) 37 (74.0) 81 (81.8) 0.066
Patients with no TEAE 5 (10.2) 13 (26.0) 18 (18.2)
Headache 19 (38.8) 9 (18.0) 28 (28.3) 0.026
Abdominal pain upper 20 (40.8) 7 (14.0) 27 (27.3) 0.003
Fatigue 16 (32.7) 9 (18.0) 25 (25.3) 0.109
Anorexia 17 (34.7) 0 (0.0) 17 (17.2) <0.001
Nausea 14 (28.6) 2 (4.0) 16 (16.2) <0.001
Vomiting 6 (12.2) 4 (8.0) 10 (10.1) 0.524
Irritability 6 (12.2) 2 (4.0) 8 (8.1) 0.159
Depressive symptom 5 (10.2) 2 (4.0) 7 (7.1) 0.268
Upper respiratory
tract infection
5 (10.2) 2 (4.0) 7 (7.1) 0.268
Pyrexia 2 (4.1) 3 (6.0) 5 (5.1) >0.999
Abdominal pain 3 (6.1) 1 (2.0) 4 (4.0) 0.362
Decreased appetite 3 (6.1) 0 (0.0) 3 (3.0) 0.117
Nasopharyngitis 0 (0.0) 3 (6.0) 3 (3.0) 0.242
N total number of patients, TEAE treatment-emergent adverse event
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heart rate were 4.6 beats/min for atomoxetine and
0.8 beats/min for placebo.
Discussion
This randomized, placebo-controlled study was the
first to investigate efficacy and safety of atomoxetine
in a population of only stimulant-naı¨ve patients.
Another uncommon feature of the study design were
the four parental psychoeducational group sessions
for the patients’ caregivers. The results confirmed the
findings from previous trials, supporting atomoxetine
as efficacious treatment of ADHD. The lsmean change
of the total ADHD-RS score from baseline to endpoint
for atomoxetine and psychoeducation was )19.0
versus )6.3 for placebo and psychoeducation. The
mean CGI-I at endpoint was 2.3 for atomoxetine
versus 3.7 for placebo, signifying that atomoxetine-
treated patients were assessed, on average, as between
‘‘minimally improved’’ and ‘‘much improved’’ com-
pared with an assessment of ‘‘no change’’ to ‘‘mini-
mally improved’’ for placebo-treated patients. Almost
two-thirds (63%) of atomoxetine-treated patients
were responders with an ADHD symptom improve-
ment from baseline to endpoint of ‡40 and 71% were
responders with an improvement of ‡25%. The ato-
moxetine treatment was well tolerated, and no dis-
continuations occurred during the double-blind study
period II. The ES for the investigator-rated ADHD-RS
total score was 1.3, which was considerably higher
than the previously published average ES across
11 investigator-rated atomoxetine trials (ES of 0.7)
and LOCF ESs of 0.6–0.8 in an overview of six other
atomoxetine trials [24, 25].
The proportion of stimulant-naı¨ve patients has
been shown to positively influence treatment response
[25]. In line with this observation, the ES in a subset
of atomoxetine-treated stimulant-naı¨ve patients was
about 0.4 units higher than in previously stimulant-
treated patients (ES of 0.9 vs. 0.5); similarly, OROS
methylphenidate-treated patients improved more if
they had been stimulant-naı¨ve before than if they had
been stimulant-treated (ES of 1.0 versus 0.8) [26].
Thus, inclusion of only stimulant-naı¨ve patients in the
present study probably reduced the study popula-
tion’s treatment resistance compared to other studies.
Response to atomoxetine also increases with
exposure to treatment and therefore might be more a
function of time than of dose [25]. In the present
study, atomoxetine-treated patients continued to im-
prove throughout the full study period of 10 weeks,
even though the main reduction of symptoms
occurred during the first 3 weeks. Placebo-treated
patients showed very little improvement beyond this
3-week time point. At endpoint, the lsmean decrease
in the ADHD-RS score for placebo-treated patients
was 6.3 points, a change very similar to that seen in
other placebo-controlled atomoxetine trials that did
not include concomitant psychoeducation: In five of
six placebo-controlled studies, each with a duration of
6–9 weeks and using investigator-rated ADHD-RS,
the mean change in the placebo-treated group varied
between 5.5 and 7.0 points [11–14], whereas corre-
sponding decreases in mean ADHD-RS scores in the
atomoxetine-treated groups of these studies varied
between 12.8 and 16.7 points; however, this was still
well below the lsmean reduction of 19.0 points ob-
served in the present study.
The absence of any premature discontinuations in
study period II, which presumably was at least in part
a result of the prospect of receiving atomoxetine in
study period III, might have added to the high ES.
The null attrition rate and the very high treatment
compliance of the study, in combination with the
ADHD-RS changes in both treatment groups, support
the assumption that parental psychoeducation inter-
acts positively with active pharmacological treatment
rather than being an efficient add-on-treatment of
ADHD per se, at least during the relatively short time
period of 10 weeks. This was supported by the results
of the parents’ evaluation of psychoeducation.
Regretfully, the study design did not allow for
matching the responses of the parents’ evaluation to
the treatment of the respective child. Nevertheless, the
absolute majority of parents appreciated receiving
more knowledge about ADHD and getting new in-
sights of more adaptive ways of coping with their
children. Simultaneously, a substantial number of
parents still perceived their children’s ADHD symp-
toms as very little or not improved at all.
The relative importance of active pharmacological
treatment compared with psychosocial interventions,
at least during a similar short time-frame as in the
present study, was demonstrated recently: ratings of
ADHD core symptoms, oppositional and conduct
behavior, parenting stress, anxiety, and self-worth
improved significantly after treatment with methyl-
phenidate alone or in combination with an intensive
10-week multimodal behavior therapy, but no signif-
icant differences were found between the outcomes of
the two treatment arms [27]. Similarly, no difference
in outcome between medication-only and medication
combined with intensive multimodal therapy was
observed in the MTA study, which compared
four treatment arms (medication with methylpheni-
date only, intensive multimodal therapy only, a
combination of both, and standard community care)
over a longer time period of 14 months [28]. How-
ever, parents preferred both conditions including
behavioral treatments over the medication-only arm,
and the combined treatment had the highest pro-
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portion of ‘‘excellent’’ responders [28, 29]. Thus, the
increased parental knowledge and awareness of the
disease and its pharmacological treatment might re-
sult in increased treatment compliance, providing a
possible synergy between pharmacological treatment
and psychoeducation. Positive effects on treatment
compliance, parenting skills, and confidence were
described in two uncontrolled studies reporting of
psychoeducational interventions similar to those in
the present study [30, 31]. In addition, good compli-
ance has another statistical implication, as particu-
larly early drop-outs, analyzed using the LOCF
principle, tend to introduce a bias for the change from
baseline to endpoint since their baseline scores are
projected to the endpoint.
ADHD is a disorder characterized by a very high
prevalence of comorbid conditions [29, 32], the most
common being oppositional defiant disorder (ODD),
occurring in 40–60% of children with the ADHD, and
conduct disorder (CD) in 14% of pediatric ADHD
patients [29, 33]. In the present study, the proportion
of patients with comorbid ODD was lower (20%) than
in many other atomoxetine trials (33–46%) [34], and
no patient fulfilled diagnostic criteria for CD. This low
prevalence of comorbid diagnoses was probably a
consequence of excluding patients requiring immedi-
ate pharmaco- and/or psychotherapy. The existing
data concerning the impact of comorbid ODD on
treatment outcome in ADHD are somewhat contra-
dictory. Generally, ODD has been associated with a
greater number of ADHD symptoms, increased ADHD
severity, and a poorer prognosis [35, 36]. However, a
similar treatment response of pediatric patients with
and without comorbid ODD has also been reported,
although comorbid patients needed higher atomoxe-
tine doses (1.8 mg/kg day) [37]. Thus, since the
present study complied with the approved EU dosing
(maximum dose around 1.2 mg/kg day), the relatively
low proportion of comorbid ODD patients may also
have contributed to the high ES of the study.
Anxiety disorders represent another ADHD
comorbidity that may impact treatment response [28,
32]. So far, the highest reported ES in any published
atomoxetine trial has been achieved in a study pop-
ulation with ADHD and comorbid anxiety disorders
(ES of 1.0) [38]. The prevalence of anxiety syndromes
(except for simple phobias) was as high as 34% in the
MTA study [29]. In contrast, the prevalence of anxiety
disorders in four North American and Non-North
American atomoxetine studies (N = 1,269), in which
the same diagnostic procedure (K-SADS-PL [20]) was
used as in the present trial, were not higher than 0.5–
2.3% [34]. Unfortunately, no systematic screening for
comorbid anxiety disorders was performed in the
present study. It is therefore not possible to evaluate
the possible effect of comorbid anxiety on the ES,
which is one obvious limitation of this study.
The exclusion of patients with need of immediate
symptom relief represents another limitation, as it
probably resulted in a study population that was not
fully representative for treatment-naı¨ve ADHD pa-
tients in Sweden. It’s even probable that investigators
to some degree preferentially enrolled patients they
expected to benefit from atomoxetine rather than
from treatment with stimulants, which represented
the only approved pharmacological treatment at the
time the study was run. However, this as well might be
regarded a concurrent advantage of the study, since
the results provide an empirically based picture of
atomoxetine, given as ‘‘first-line’’ treatment, in com-
bination with parental psychoeducation.
With regards to safety, atomoxetine was well tol-
erated and did not cause any serious AEs or pre-
mature discontinuations. The safety profile was in line
with the profile known from other atomoxetine
studies and consistent with the label for atomoxetine.
A significantly higher incidence among atomoxetine
patients compared to placebo patients was observed
for the AEs headache, abdominal pain upper, anor-
exia, and nausea.
Conclusions
This is the first published study comparing only
stimulant-naı¨ve ADHD patients treated with ato-
moxetine or placebo in combination with concurrent
parental psychoeducation. Potentially, psychoeduca-
tion was the reason for improved treatment compli-
ance both in placebo- and atomoxetine-treated
patients, in spite of significant parental recognition of
limited or absent treatment response in about half of
the patients. No patients discontinued the study.
Inclusion of only treatment-naı¨ve patients and pa-
tients who, in the opinion of the investigator, were
more likely to respond to atomoxetine than to stim-
ulants, may have added to the superior efficacy of
atomoxetine treatment over placebo. The 10-week
duration of the double-blind study period, which was
long enough for the full treatment effect of ato-
moxetine to develop, may also have contributed to the
good efficacy. Atomoxetine treatment was well toler-
ated with a safety profile in line with the current label.
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